Evidence map›Paper›PMID 34451815›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Antonia Windkouni Bere, Omuyundo Mulati, James Kimotho, Florence Ng'ong'a

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Prospects ofHeliyon · 2024
    Article
  7. Article
  8. Heliyon · 2022
    Article
  9. Delving into the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2022
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Antonia Windkouni BereDepartment of Molecular Biology and Biotechnology, Pan African University Institute for Basic Sciences, Technology and Innovation, Nairobi P.O. Box 62000-00200, Kenya.
Omuyundo MulatiDepartment of Biomedical Sciences and Technology, Technical University of Kenya, Nairobi P.O. Box 52428-00200, Kenya.
James KimothoInnovation and Technology Transfer Division, Kenya Medical Research Institute, Nairobi P.O. Box 54840-00200, Kenya.
Florence Ng'ong'aDepartment of Biochemistry, Jomo Kenyatta University of Agriculture and Technology, Nairobi P.O. Box 62000-00200, Kenya.
Jomo Kenyatta University of Agriculture and Technology · KEKenya Medical Research Institute · KEPan African University Institute for Basic Sciences, Technology and InnovationTechnical University of Kenya · KE

Funding

Pan Africa University 6th cohort
6 · The paper itself

Abstract

The current global occurrence of dengue infection annually is approximately 400 million, with a case fatality rate of 2.5%. However, there are no antiviral agents.

Indexed as

antiviral activityCarica papayadengue virussilver nanoparticles

Identifiers

PMID34451815
PMCPMC8400503
OpenAlexW3186928214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.